Haiyan Liu

Haiyan Liu serves as the Sr. Director of Quality Control at Obsidian Therapeutics as of November 2023. Prior to this role, Haiyan operated as the Executive Director of Analytical Science and Technology at the Gene Therapy Program at the University of Pennsylvania from September 2022 to November 2023. Previous positions include Executive Director of Analytical Development and Quality Control at WuXi Advanced Therapies, Director of Quality Control and Analytical Technologies at Rubius Therapeutics, and Group Leader of Analytical Development at bluebird bio. Haiyan also held the position of Analytical Product Lead at Bristol Myers Squibb and worked as an Investigator in Analytical Development at GSK for over 17 years. Haiyan holds a Master of Science in Molecular Biology from the University of North Texas and a Bachelor of Science in Microbiology from Xiamen University.